Atara Biotherapeutics, Inc.
ATRA· Nasdaq
Released Aug 12, 2024, after the close
10-Q filed Aug 12, 2024, 43 days after period end · 0000950170-24-095533
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $28.64M | $957.00K | $51.58M | — |
| Net Income | -$19.05M | -$71.11M | $18.47M | -$83.79M |
| EPS Diluted |
Atara Biotherapeutics, Inc. · CIK 1604464 · Engraved from SEC EDGAR
| -$3.10 |
| -$16.91 |
| $0.18 |
| -$0.91 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.